Since 2015 OncoLytika have been partners in a networking grant looking at the advances in fit-for-use manufacturing of biopharmaceutical drug delivery and pharmaceutical systems that are now required to fit Quality by Design (QbD) models.
The EHDA network brings together specialists from academia and industry to advance this technology through several means. Firstly, initiating developments towards a real-viable scale for Pharmaceutical production. Secondly, to incorporate developments in lean manufacturing and legislation (e.g. continuous manufacturing, online diagnostics, QbD and adaptable scale). Thirdly, to marry optimised lean technologies with novel and emerging macromolecular therapies and actives.
The network has a wide range of activities and initiatives which will lead to significant developments (and collaborations) in an area of increasing global interest (EHDA processes) - but currently only on a viable lab scale to date. This network will be the first of its kind and will serve as the central and pioneering hub in this remit.
Partners include several UK higher education institutions, as well as bio-tech companies such as GlaxoSmithKline.
For more information see here.
OncoLytika is proud to be part of an exciting research project led by De Montfort University studying Biopharmaceutical Stability at Room Temperature, also known as BioStaRT.
BioStaRT is an Innovate UK funded collaborative R&D project aimed at developing new analytical technologies to assist in the development of room temperature stable freeze-dried biopharmaceuticals. Stability at room temperature will extend shelf life and reduce the cold chain costs of refrigerated transportation and storage.
Other partners in the project include, GEA Process Engineering, National Institute for Biological Standards and Control, Genzyme Ireland, Blue Frog Design and De Montfort University.
For more information see here.
|
|
|